- CA$10.88m
- CA$13.74m
Annual balance sheet for Hemostemix, fiscal year end - December 31st, CAD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 0.219 | 0.136 | 0.155 | 0.706 | 0.742 |
| Net Total Receivables | 0.343 | 0.139 | 0.025 | 0.23 | 0.066 |
| Prepaid Expenses | |||||
| Total Current Assets | 0.562 | 0.465 | 0.314 | 0.992 | 0.847 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 0.001 | 0 | 0 | 0 | 0 |
| Net Intangible Assets | |||||
| Total Assets | 0.563 | 0.465 | 0.314 | 0.992 | 0.847 |
| Payable / Accrued | |||||
| Notes Payable / Short Term Debt | |||||
| Total Current Liabilities | 4.37 | 2.62 | 2.88 | 2.77 | 1.73 |
| Long Term Debt | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Deferred Income Tax | |||||
| Total Liabilities | 5.85 | 7.23 | 7.68 | 8.2 | 5.82 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | -5.28 | -6.77 | -7.37 | -7.2 | -4.97 |
| Total Liabilities & Shareholders' Equity | 0.563 | 0.465 | 0.314 | 0.992 | 0.847 |
| Total Common Shares Outstanding |